Clinical Evidence: Diabetes
the SURPASS program -- five phase 3 trials that established tirzepatide as the most effective incretin therapy
The Trial Program That Changed the Standard
The SURPASS clinical program comprised five pivotal phase 3 trials enrolling over 6,000 adults with type 2 diabetes. Across every comparator -- placebo, semaglutide 1mg, insulin degludec, and insulin glargine -- tirzepatide demonstrated superior HbA1c reductions and weight loss. SURPASS-2, the head-to-head trial against semaglutide, was the landmark: tirzepatide at all three doses outperformed the leading GLP-1 agonist on both primary and key secondary endpoints. This unit walks through the evidence trial by trial.
SURPASS Trial Comparison
Compare outcomes across all five SURPASS trials and see how tirzepatide performed against each comparator.